No differences of immune activation and microbial translocation among HIV-infected children receiving combined antiretroviral therapy or protease inhibitor monotherapy.

This is a cross-sectional study of 15 aviremic chronic HIV-infected children revealing no differences in immune activation (IA; HLA-DRCD38 CD4 and CD8 T cells, and sCD14) and microbial translocation (MT; lipopolysaccharides (LPS) and 16S rDNA) among HIV-infected patients under combined antiretrovira...

Full description

Bibliographic Details
Authors: Falcon Neyra, Lola, Benmarzouk-Hidalgo, Omar J., Madrid, Lola, Noguera Julian, Antoni, Fortuny Guasch, Claudia, Neth, Olaf, López Cortés, Luis F.
Format: article
Status:Published version
Publication Date:2015
Country:España
Institution:Universidad de Barcelona
Repository:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/105795
Online Access:https://hdl.handle.net/2445/105795
Access Level:Open access
Keyword:Infants
Infeccions per VIH
Antiretrovirals
Inhibidors enzimàtics
Children
HIV infections
Antiretroviral agents
Enzyme inhibitors
Description
Summary:This is a cross-sectional study of 15 aviremic chronic HIV-infected children revealing no differences in immune activation (IA; HLA-DRCD38 CD4 and CD8 T cells, and sCD14) and microbial translocation (MT; lipopolysaccharides (LPS) and 16S rDNA) among HIV-infected patients under combined antiretroviral treatment (cART; n = 10) or ritonavir-boosted protease inhibitor monotherapy (mtPI/rtv; n = 5). In both cases, IA and MT were lower in healthy control children (n = 32). This observational study suggests that ritonavir boosted protease inhibitor monotherapy (mtPI/rtv) is not associated with an increased state of IA or MT as compared with children receiving cART.

Similar Items